• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型双腔气管内导管在呼吸窘迫综合征早产儿中的应用:一项非劣效性随机对照试验(NISA)的研究方案

Application of a new type of double-lumen endotracheal tube in preterm infants with respiratory distress syndrome: study protocol for a non-inferiority randomised controlled trial (NISA).

作者信息

Gao Jin, Xiong Hanmei, Nie Panrong, Yang Hong, Li Dan, Deng Xingmei, Shi Yuan, Li Chuanfeng, Yu Weihong, Yang Jie, Du Yuxuan

机构信息

Department of Neonatology, Children's Hospital of Chongqing Medical University, Chongqing, Chongqing, China.

Department of Neonatology, The First People's Hospital of Zhaotong, Zhaotong, Yunnan, China.

出版信息

BMJ Open. 2024 Dec 9;14(12):e083508. doi: 10.1136/bmjopen-2023-083508.

DOI:10.1136/bmjopen-2023-083508
PMID:39653560
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11628960/
Abstract

BACKGROUND

Non-invasive ventilation combined with pulmonary surfactant (PS) therapy is recognised as a method for treating neonatal respiratory distress syndrome (NRDS). Among the administration, methods of PS, INtubation-SURfactant-Extubation (InSurE) and less invasive surfactant administration (LISA) have been widely discussed.LISA technique prevents patients from exposure to invasive positive pressure ventilation (PPV), thus improving the long-term outcomes of the respiratory system, but it faces challenges in resource-limited areas due to complexity and cost. The InSurE technique remains prevalent due to its simplicity. The new dual-lumen tracheal tube (NDT) is designed with a 0.2 mm diameter pathway on the sidewall for continuous administration of PS under continuous PPV. The purpose of this study is to compare the safety and effectiveness of the NDT InSurE technique versus the LISA technique in non-invasive ventilation for premature infants with NRDS, and to explore the applicability of the NDT.

METHODS AND ANALYSIS

This is a multicentre randomised controlled trial, planned to recruit 132 premature infants who meet the inclusion criteria from January 2024 to December 2024. They will be randomly assigned to the InSurE group using the NDT (experimental group) and the LISA group. The study will be conducted in six tertiary neonatal intensive care units in Yunnan province. The primary outcome is the rate of mechanical ventilation within 72 hours after birth. Secondary outcomes include the procedure data and major complications of NRDS, also include respiratory infections within 12 months of corrected age.

DISCUSSION

We assume that the NDT is not worse than the LISA catheter. Based on the characteristics of the NDT, continuous PPV during drug administration, we designed this study to compare the InSurE technique using the NDT with the LISA technique. We aim to explore more benefits of the NDT and confirm wider clinical applicability. It will provide more options for doctors when using the InSurE technique.

ETHICS AND DISSEMINATION

This study complies with the Declaration of Helsinki and was approved by the medical ethics committee of Kunming Children's Hospital (approval number 2023-03-297-K01) and theoretical committee of Qujing Maternal and Child Health Hospital. At the end of the study, we will organise the data, complete the statistical analysis and present our research findings in the form of a paper.There is lack of comparative research on the NDT InSurE technique and LISA, making this study innovative. If the hypothesis is confirmed, clinicians will have an additional option when using PS, and it may even replace endotracheal tube in InSurE technique. The limited number of preterm infants planned for recruitment in the study may restrict stratified analyses based on gestational age, which could affect the broad applicability of the study results. The study is limited to preterm infants with a gestational age of less than 32 weeks, which means that the results may not be applicable to preterm infants with a larger gestational age or other patient populations.

摘要

背景

无创通气联合肺表面活性物质(PS)治疗被认为是治疗新生儿呼吸窘迫综合征(NRDS)的一种方法。在PS的给药方法中,气管插管-肺表面活性物质-拔管(InSurE)和微创肺表面活性物质给药(LISA)已被广泛讨论。LISA技术可防止患者暴露于有创正压通气(PPV),从而改善呼吸系统的长期预后,但由于其复杂性和成本,在资源有限的地区面临挑战。InSurE技术因其简单性而仍然普遍使用。新型双腔气管导管(NDT)在侧壁上设计有直径0.2毫米的通道,用于在持续PPV下持续给药PS。本研究的目的是比较NDT InSurE技术与LISA技术在无创通气治疗NRDS早产儿中的安全性和有效性,并探索NDT的适用性。

方法与分析

这是一项多中心随机对照试验,计划于2024年1月至2024年12月招募132名符合纳入标准的早产儿。他们将被随机分配到使用NDT的InSurE组(实验组)和LISA组。该研究将在云南省的六个三级新生儿重症监护病房进行。主要结局是出生后72小时内的机械通气率。次要结局包括NRDS的操作数据和主要并发症,还包括矫正年龄12个月内的呼吸道感染。

讨论

我们假设NDT不劣于LISA导管管。基于NDT的特点,即给药期间持续PPV,我们设计了本研究以比较使用NDT的InSurE技术与LISA技术。我们旨在探索NDT的更多益处并确认其更广泛的临床适用性。这将在使用InSurE技术时为医生提供更多选择。

伦理与传播

本研究符合《赫尔辛基宣言》,并获得昆明市儿童医院医学伦理委员会(批准文号2023-03-297-K01)和曲靖市妇幼保健院伦理委员会的批准。在研究结束时,我们将整理数据,完成统计分析,并以论文形式展示我们的研究结果。目前缺乏关于NDT InSurE技术和LISA的比较研究,使得本研究具有创新性。如果假设得到证实,临床医生在使用PS时将有额外的选择,甚至可能在InSurE技术中取代气管内导管。本研究计划招募的早产儿数量有限,可能会限制基于胎龄的分层分析,这可能会影响研究结果的广泛适用性。该研究仅限于胎龄小于32周的早产儿,这意味着结果可能不适用于胎龄较大的早产儿或其他患者群体。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf8c/11628960/60ae762ea2d9/bmjopen-14-12-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf8c/11628960/b650718a80ee/bmjopen-14-12-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf8c/11628960/baf7e648d745/bmjopen-14-12-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf8c/11628960/60ae762ea2d9/bmjopen-14-12-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf8c/11628960/b650718a80ee/bmjopen-14-12-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf8c/11628960/baf7e648d745/bmjopen-14-12-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bf8c/11628960/60ae762ea2d9/bmjopen-14-12-g003.jpg

相似文献

1
Application of a new type of double-lumen endotracheal tube in preterm infants with respiratory distress syndrome: study protocol for a non-inferiority randomised controlled trial (NISA).新型双腔气管内导管在呼吸窘迫综合征早产儿中的应用:一项非劣效性随机对照试验(NISA)的研究方案
BMJ Open. 2024 Dec 9;14(12):e083508. doi: 10.1136/bmjopen-2023-083508.
2
The influence of the technique of surfactant administration (LISA vs INSURE) on the outcomes of respiratory distress syndrome treatment in preterm infants.表面活性剂给药技术(肺内滴注法与气管插管-肺表面活性物质给药法)对早产儿呼吸窘迫综合征治疗结局的影响。
Dev Period Med. 2019;23(3):163-171. doi: 10.34763/devperiodmed.20192303.163171.
3
Less invasive surfactant administration versus endotracheal surfactant instillation followed by limited peak pressure ventilation in preterm infants with respiratory distress syndrome in China: study protocol for a randomized controlled trial.经鼻给予肺表面活性物质与气管内给予肺表面活性物质后行小潮气量通气治疗中国呼吸窘迫综合征早产儿的随机对照试验研究方案
Trials. 2020 Jun 11;21(1):516. doi: 10.1186/s13063-020-04390-3.
4
Comparison of "IN-REC-SUR-E" and LISA in preterm neonates with respiratory distress syndrome: a randomized controlled trial (IN-REC-LISA trial).“IN-REC-SUR-E”与 LISA 在呼吸窘迫综合征早产儿中的比较:一项随机对照试验(IN-REC-LISA 试验)。
Trials. 2024 Jul 2;25(1):433. doi: 10.1186/s13063-024-08240-4.
5
Surfactant administration in preterm babies (28-36 weeks) with respiratory distress syndrome: LISA versus InSurE, an open-label randomized controlled trial.表面活性物质在有呼吸窘迫综合征的早产儿(28-36 周)中的应用:LISA 与 InSurE,一项开放标签随机对照试验。
Pediatr Pulmonol. 2023 Mar;58(3):738-745. doi: 10.1002/ppul.26246. Epub 2022 Dec 1.
6
Minimally invasive surfactant therapy versus InSurE in preterm neonates of 28 to 34 weeks with respiratory distress syndrome on non-invasive positive pressure ventilation-a randomized controlled trial.经鼻持续气道正压通气治疗的 28 至 34 周呼吸窘迫综合征早产儿应用微创肺表面活性物质治疗与 InSurE 的随机对照研究。
Eur J Pediatr. 2020 Aug;179(8):1287-1293. doi: 10.1007/s00431-020-03682-9. Epub 2020 May 27.
7
Less invasive surfactant administration versus intubation for surfactant delivery in preterm infants with respiratory distress syndrome: a systematic review and meta-analysis.在患有呼吸窘迫综合征的早产儿中,与插管给药相比,采用侵入性较小的表面活性剂给药方式:一项系统评价和荟萃分析。
Arch Dis Child Fetal Neonatal Ed. 2017 Jan;102(1):F17-F23. doi: 10.1136/archdischild-2015-310299. Epub 2016 Nov 15.
8
Less Invasive Surfactant Administration (LISA) vs. Intubation Surfactant Extubation (InSurE) in Preterm Infants with Respiratory Distress Syndrome: A Pilot Randomized Controlled Trial.经鼻持续气道正压通气与肺表面活性物质治疗早产儿呼吸窘迫综合征的随机对照研究
J Trop Pediatr. 2021 Aug 27;67(4). doi: 10.1093/tropej/fmab086.
9
Less Invasive Surfactant Administration in Preterm Infants with Respiratory Distress Syndrome.在患有呼吸窘迫综合征的早产儿中进行的微创表面活性剂给药
J Coll Physicians Surg Pak. 2019 Mar;29(3):226-330. doi: 10.29271/jcpsp.2019.03.226.
10
Surfactant therapy via thin catheter in preterm infants with or at risk of respiratory distress syndrome.经细导管给予表面活性物质治疗有或有发生呼吸窘迫综合征风险的早产儿。
Cochrane Database Syst Rev. 2021 May 10;5(5):CD011672. doi: 10.1002/14651858.CD011672.pub2.

本文引用的文献

1
Respiratory Management of the Preterm Infant: Supporting Evidence-Based Practice at the Bedside.早产儿的呼吸管理:支持床边循证实践
Children (Basel). 2023 Mar 10;10(3):535. doi: 10.3390/children10030535.
2
Safety and efficacy of a novel double-lumen tracheal tube in neonates with RDS: A prospective cohort study.一种新型双腔气管导管在新生儿呼吸窘迫综合征中的安全性和有效性:一项前瞻性队列研究。
Front Pediatr. 2022 Dec 5;10:1032044. doi: 10.3389/fped.2022.1032044. eCollection 2022.
3
Bronchopulmonary dysplasia.支气管肺发育不良
Paediatr Anaesth. 2022 Feb;32(2):174-180. doi: 10.1111/pan.14365. Epub 2021 Dec 15.
4
A systematic review of surfactant delivery via laryngeal mask airway, pharyngeal instillation, and aerosolization: Methods, limitations, and outcomes.经喉罩气道、咽灌洗和雾化给予表面活性剂的系统评价:方法、局限性和结果。
Pediatr Pulmonol. 2022 Jan;57(1):9-19. doi: 10.1002/ppul.25698. Epub 2021 Sep 29.
5
International Classification of Retinopathy of Prematurity, Third Edition.国际早产儿视网膜病变分类,第三版。
Ophthalmology. 2021 Oct;128(10):e51-e68. doi: 10.1016/j.ophtha.2021.05.031. Epub 2021 Jul 8.
6
Surfactant therapy via thin catheter in preterm infants with or at risk of respiratory distress syndrome.经细导管给予表面活性物质治疗有或有发生呼吸窘迫综合征风险的早产儿。
Cochrane Database Syst Rev. 2021 May 10;5(5):CD011672. doi: 10.1002/14651858.CD011672.pub2.
7
Outcomes after Introduction of Minimally Invasive Surfactant Therapy in Two Australian Tertiary Neonatal Units.澳大利亚两家三级新生儿单位引入微创表面活性剂治疗后的结果。
J Pediatr. 2021 Feb;229:141-146. doi: 10.1016/j.jpeds.2020.10.025. Epub 2020 Oct 14.
8
Defining necrotizing enterocolitis: current difficulties and future opportunities.定义坏死性小肠结肠炎:当前的困难和未来的机遇。
Pediatr Res. 2020 Aug;88(Suppl 1):10-15. doi: 10.1038/s41390-020-1074-4.
9
Less invasive surfactant administration versus endotracheal surfactant instillation followed by limited peak pressure ventilation in preterm infants with respiratory distress syndrome in China: study protocol for a randomized controlled trial.经鼻给予肺表面活性物质与气管内给予肺表面活性物质后行小潮气量通气治疗中国呼吸窘迫综合征早产儿的随机对照试验研究方案
Trials. 2020 Jun 11;21(1):516. doi: 10.1186/s13063-020-04390-3.
10
Minimally invasive surfactant therapy versus InSurE in preterm neonates of 28 to 34 weeks with respiratory distress syndrome on non-invasive positive pressure ventilation-a randomized controlled trial.经鼻持续气道正压通气治疗的 28 至 34 周呼吸窘迫综合征早产儿应用微创肺表面活性物质治疗与 InSurE 的随机对照研究。
Eur J Pediatr. 2020 Aug;179(8):1287-1293. doi: 10.1007/s00431-020-03682-9. Epub 2020 May 27.